<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26668">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02759562</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-404-1808</org_study_id>
    <secondary_id>2015-002192-23</secondary_id>
    <nct_id>NCT02759562</nct_id>
  </id_info>
  <brief_title>Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis</brief_title>
  <official_title>A Phase 2b, Dose-Ranging Study of the Effect of GS-5745 on FEV1 in Adult Subjects With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of andecaliximab (formerly GS-5745) on
      pre-bronchodilator FEV1 in adults with cystic fibrosis (CF) after 8 weeks of treatment.

      There will be 2 parts to this study. In Part 1, andecaliximab 600 mg or placebo will be
      administered for 8 weeks. In Part 2, andecaliximab 300 mg, 150 mg, or placebo will be
      administered for 8 weeks. Part 2 will be initiated after completion of Part 1.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change in pre-bronchodilator FEV1 percent predicted from Baseline to Week 8</measure>
    <time_frame>Baseline; Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in post-bronchodilator FEV1 percent predicted from Baseline to Week 8</measure>
    <time_frame>Baseline; Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative change in pre-bronchodilator FEV1 percent predicted from Baseline to Week 8</measure>
    <time_frame>Baseline; Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative change in post-bronchodilator FEV1 percent predicted from Baseline to Week 8</measure>
    <time_frame>Baseline; Week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Andecaliximab 600 mg (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Andecaliximab 600 mg weekly for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part 1)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo weekly for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Andecaliximab 300 mg (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Andecaliximab 300 mg weekly for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Andecaliximab 150 mg (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Andecaliximab 150 mg + placebo weekly for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part 2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo weekly for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open-Label Extension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Part 1) Andecaliximab 600 mg weekly for 16 weeks; (Part 2) Andecaliximab 300 mg weekly for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Andecaliximab</intervention_name>
    <description>Administered subcutaneously</description>
    <arm_group_label>Andecaliximab 600 mg (Part 1)</arm_group_label>
    <arm_group_label>Andecaliximab 300 mg (Part 2)</arm_group_label>
    <arm_group_label>Andecaliximab 150 mg (Part 2)</arm_group_label>
    <arm_group_label>Open-Label Extension</arm_group_label>
    <other_name>GS-5745</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered subcutaneously</description>
    <arm_group_label>Placebo (Part 1)</arm_group_label>
    <arm_group_label>Andecaliximab 150 mg (Part 2)</arm_group_label>
    <arm_group_label>Placebo (Part 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Confirmed diagnosis of CF as determined by the 2008 Cystic Fibrosis Foundation
             Consensus Report criteria

          -  Must have a body weight of &gt; 40 kg (88.2 lb) at study screening

          -  Pre-bronchodilator FEV1 ≥ 40% and ≤ 80% of predicted at screening

          -  Two pre-bronchodilator spirometry measures during screening and baseline must meet
             the following 2 criteria:

               -  The relative difference of FEV1(L), calculated as the absolute value of [(first
                  FEV1 - second FEV1) / first FEV1] x 100 should be &lt; 12% AND

               -  The absolute difference in FEV1 should be &lt; 200 ml

          -  Negative Sputum Investigation/History of any Mycobacterium spp. or Burkholderia spp.
             per specified protocol-defined time periods

          -  Clinically stable with no evidence of significant respiratory symptoms that would
             require administration of IV antibiotics, oxygen supplementation, or hospitalization
             within 30 days of baseline.

          -  On stable CF chronic medical regimen for at least 30 days prior to baseline and
             expected to remain stable through the completion of the study. This includes but is
             not limited to: chronic azithromycin use, inhaled bronchodilators, inhaled
             corticosteroids, inhaled dornase alpha, inhaled hypertonic saline, inhaled mannitol,
             ivacaftor, and/or ivacaftor/lumacaftor.

        Key Exclusion Criteria:

          -  Concurrent use of oral antibiotics (excluding chronic azithromycin use) or IV
             antibiotics within 30 days of baseline. Prophylactic and chronic doxycycline use is
             prohibited during the study.

          -  Hospitalization for a respiratory event within 30 days of baseline

          -  Current use of systemic immunosuppressive drugs including oral corticosteroids within
             30 days of Baseline

          -  Current requirement for daily continuous oxygen supplementation or requirement
             (medically necessary) of more than 2 L/minute at night (subject would not meet this
             exclusion criterion if supplemental oxygen is used for comfort only)

          -  History of solid organ (including lung) or hematologic transplant, or currently on a
             transplant waiting list

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Study Team</last_name>
    <email>GS-US-404-1808@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Glenview</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>New Lambton</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Brittany</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Montepellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Pierre Benite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 7, 2017</lastchanged_date>
  <firstreceived_date>April 29, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
